Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
The risks that can come from buying these assets is precisely why we started StockStory - to isolate the long-term winners from the losers so you can invest with confidence. That said, here is one growth stock expanding its competitive advantage and two climbing an uphill battle.
Two Growth Stocks to Sell:
Vital Farms (VITL)
One-Year Revenue Growth: +25.3%
With an emphasis on ethically produced products, Vital Farms (NASDAQ: VITL) specializes in pasture-raised eggs and butter.
Why Are We Cautious About VITL?
- Subscale operations are evident in its revenue base of $759.4 million, meaning it has fewer distribution channels than its larger rivals
- Free cash flow margin shrank by 12.3 percentage points over the last year, suggesting the company is consuming more capital to stay competitive
At $12.75 per share, Vital Farms trades at 12.3x forward P/E. Read our free research report to see why you should think twice about including VITL in your portfolio.
The Real Brokerage (REAX)
One-Year Revenue Growth: +55.7%
Founded in Toronto, Canada in 2014, The Real Brokerage (NASDAQ: REAX) is a technology-driven real estate brokerage firm combining a tech-centric model with an agent-centric philosophy.
Why Do We Steer Clear of REAX?
- Operating margin of -0.8% falls short of the industry average, and the smaller profit dollars make it harder to react to unexpected market developments
- Earnings growth underperformed the sector average over the last four years as its EPS grew by just 8.9% annually
- Forecasted free cash flow margin suggests the company will fail to improve its cash conversion over the next year
The Real Brokerage’s stock price of $2.57 implies a valuation ratio of 6.3x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than REAX.
One Growth Stock to Watch:
Doximity (DOCS)
One-Year Revenue Growth: +15.9%
With over 80% of U.S. physicians as members of its digital community, Doximity (NYSE: DOCS) operates a digital platform that enables physicians and other healthcare professionals to collaborate, stay current with medical news, manage their careers, and conduct virtual patient visits.
Why Does DOCS Stand Out?
- Annual revenue growth of 29.3% over the past five years was outstanding, reflecting market share gains
- User-friendly software enables clients to ramp up spending quickly, leading to the speedy recovery of customer acquisition costs
- Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends
Doximity is trading at $22.28 per share, or 6.7x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
